STOCK TITAN

Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Evelo Biosciences (Nasdaq: EVLO), a clinical stage biotechnology firm, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 2:15 p.m. ET. The presentation will be accessible via a live audio webcast on Evelo's investor website, with a replay available for 30 days post-event. Evelo specializes in developing orally delivered medicines targeting the small intestinal axis (SINTAX) to achieve systemic therapeutic effects. Their product candidates include EDP1815, EDP1867, EDP2939 for inflammatory diseases, and EDP1908 for cancer.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET.

A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX™, the small intestinal axis, and to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn and video.

Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com


FAQ

When will Evelo Biosciences present at the Needham Healthcare Conference?

Evelo Biosciences will present on April 12, 2021, at 2:15 p.m. ET.

How can I access the Evelo Biosciences presentation?

The presentation will be available via a live audio webcast on Evelo's investor website.

What are the main products in development by Evelo Biosciences?

Evelo is developing EDP1815, EDP1867, and EDP2939 for inflammatory diseases, and EDP1908 for cancer.

What is the focus of Evelo Biosciences' research?

Evelo focuses on orally delivered medicines that target the small intestinal axis (SINTAX) for systemic therapeutic effects.

Where can I find more information about Evelo Biosciences?

More information can be found on Evelo's website at www.evelobio.com.

EVELO BIOSCIENCES INC

OTC:EVLO

EVLO Rankings

EVLO Latest News

EVLO Stock Data

958.63k
18.86M
0.14%
13.16%
1.04%
Biotechnology
Healthcare
Link
United States of America
Cambridge